Orthocell Ltd (ASX:OCC) has been granted a trading halt by the ASX this morning, pending details in relation to its application for European regulatory approval (CE Mark) of its CelGro® collagen medical device.
CelGro® is a collagen medical device platform for soft tissue regeneration and repair applications.
The CE Mark would provide commercialisation opportunities.
The halt will remain in place until the opening of trade on Friday 10th November 2017, or earlier if an announcement is made to the market.